TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1422321
Drug: 0.15 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/day of conjugated estrogens
Study: 1422321
Drug: 0.30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/day of conjugated estrogens
Study: 1422321
Drug: 0.15 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Study: 1422321
Drug: 0.30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Study: 2475690
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of verapamil
Study: 31613320
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (HD) group took 4 mg 17ß‐estradiol/d orally.
Study: 31613320
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (LD) group took 2 mg 17ß‐estradiol/d orally and placebo.
Study: 20388497
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (CHO)
Study: 26034927
Drug: Alpha lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid (ALA) 600 mg/day
Study: 24103510
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and copper syrup with zinc (10 mg of iron, 0.5 mg of copper, and 10 mg of zinc)
Study: 24103510
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and copper syrup without zinc (10 mg of iron and 0.5 mg of copper)
Study: 11128679
Drug: Probenecid and
Normalized name: Probenecid and Colchicine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid and aspirin 325 mg taken concomitantly
Study: 11128679
Drug: Probenecid followed
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid followed by aspirin 325 mg at 6 hours
Study: 1478369
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (continuous subcutaneous insulin infusion)
Study: 6487749
Drug: Ketoprofen capsules
Normalized name: Ketoprofen Capsules
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen capsules (200 mg)
Study: 6487749
Drug: Sustained-release pellets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release pellets (200 mg)
Study: 6487749
Drug: Sustained-release pellets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release pellets (200 mg) once every 24 h
Study: 6487749
Drug: Ketoprofen capsules
Normalized name: Ketoprofen Capsules
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen capsules (50 mg) every 6 h
Study: 30323322
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (5-day course)
Study: 22748702
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg twice daily
Study: 24593917
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (annual treatment)
Study: 24593917
Drug: Annual treatment
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual treatment with oral azithromycin
Study: 20699411
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 25 mg [(14)C]INCB018424
Study: 20699411
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses of unlabeled INCB018424
Study: 15773875
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulphate (40 mg daily)
Study: 12114361
Drug: Clarithromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (400 mg/d for 7 days)
Study: 12114361
Drug: Amoxicillin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1,500 mg/d for 7 days)
Study: 12114361
Drug: Cefaclor (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (750 mg/d for 7 days)
Study: 20180109
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (2 microg/kg)
Study: 1459356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GIP and GLP-1 [7-36 amide]
Study: 22500712
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (1 bag/dose, two doses per day)
Study: 12885685
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d) with Primary Care Management (PCM)
Study: 12885685
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d) with Cognitive Behavior Therapy (CBT)
Study: 10369493
Drug: Chitosan (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (four capsules twice daily for 28 days)
Study: 10369493
Drug: Placebo (indistinguishable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (indistinguishable capsules, four capsules twice daily for 28 days)
Study: 30207136
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg, followed by an infusion of 0.4 μg/kg/h
Study: 23626461
Drug: Saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 2.5 mg
Study: 23626461
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg
Study: 21342412
Drug: Saxagliptin 10
Normalized name: Dapagliflozin/Saxagliptin 10 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 10 mg
Study: 15690976
Drug: Human neuronal
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human neuronal cells (hNT cells; LBS neurons) delivered in doses of 2 or 6 million cells in three or nine implants, or 5 or 10 million cells in 25 implants
Study: 787957
Drug: Propranolol (80-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80-320 mg daily, with increments up to 1200 mg as needed)
Study: 787957
Drug: Tranquilizers (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranquilizers (control group)
Study: 31931026
Drug: Mock treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock treatment (control)
Study: 28430638
Drug: TACE+C+L
Normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE+C+L
Study: 26293519
Drug: Piperaquine-dihydroartemisinin administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperaquine-dihydroartemisinin administered after a high-fat, high-calorie meal
Study: 26293519
Drug: Piperaquine-dihydroartemisinin administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperaquine-dihydroartemisinin administered after fasting
Study: 28698335
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs
Study: 28698335
Drug: Standard antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiepileptic drugs
Study: 9525716
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with CCNU, vincristine, and prednisone
Study: 9525716
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with eight-drugs-in-1-day regimen
Study: 7787157
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg h.s.
Study: 2568086
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg h.s.
Study: 28142202
Drug: Deferasirox film-coated
Normalized name: deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox film-coated tablet (FCT)
Study: 26092557
Drug: Docetaxel chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy plus androgen deprivation therapy (ADT)
Study: 23533230
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) alone
Study: 18972062
Drug: Cu-(II)-orotate-dihydrate (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cu-(II)-orotate-dihydrate (8 mg Cu daily)
Study: 16550600
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin 100 mg/m2 day 1 and etoposide 120 mg/m2 days 1-3 for 6 cycles)
Study: 16550600
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin and etoposide)
Study: 12963761
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of acetaminophen, given six times daily
Study: 7917773
Drug: lazabemide (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: lazabemide (100-300 mg single dose and 100-350 mg twice daily for 7 days)
Study: 2844876
Drug: Leukotriene E4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene E4 (lower dose)
Study: 2844876
Drug: Leukotriene E4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene E4 (higher dose)
Study: 18492534
Drug: Pravastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy (20 to 40 mg)
Study: 16567913
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of magnesium sulphate 250 mg/kg within half an hour of birth and subsequently 125 mg/kg at 24 and 48 hours of life
Study: 7982415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no magnesium treatment)
Study: 1286497
Drug: Flumazenil (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (mean dose: 0.73 mg)
Study: 1286497
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean dose: 8.9 ml)
Study: 28984909
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine
Study: 30924578
Drug: fast-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: fast-acting insulin aspart (faster aspart)
Study: 26962719
Drug: Gabapentin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (maximum dose 1200 mg three times a day)
Study: 10593710
Drug: Various fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various fixed-dose combination (FDC) formulations of rifampicin
Study: 10593710
Drug: Reference administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference administered as loose (separate) formulations
Study: 8618186
Drug: Subcutaneous Epo
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous Epo (200 units/kg per day for 10 days)
Study: 8618186
Drug: Epo in
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epo in TPN solution (200 units/kg per day for 10 days)
Study: 8618186
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (subcutaneous and TPN)
Study: 7100224
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg intravenously before and every 8 hours for the first 72 hours post-operatively
Study: 31634729
Drug: Standard antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiepileptic drugs (AEDs)
Study: 29217600
Drug: Extra-fine beclometasone/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-fine beclometasone/formoterol maintenance and reliever therapy (MART)
Study: 24423311
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion (2 pmol × kg(‐1) × min(‐1))
Study: 20665055
Drug: Ropivacaine (0.2%)
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine (0.2%) alone, 0.7 ml/kg (Group R)
Study: 20665055
Drug: Ropivacaine (0.2%)
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine (0.2%) plus tramadol (2 mg/kg), total volume 0.7 ml/kg (Group RT)
Study: 20665055
Drug: Ropivacaine (0.2%)
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine (0.2%) plus tramadol (2 mg/kg) (Group RT)
Study: 15201783
Drug: Intravesical resiniferatoxin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical resiniferatoxin (0.6 microM in 50 ml of 0.9% NaCl)
Study: 15201783
Drug: Botulinum-A toxin
Normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum-A toxin injections (300 units diluted in 30 ml 0.9% NaCl)
Study: 9792371
Drug: 3TC (lamivudine)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3TC (lamivudine) syrup or tablets (4 mg/kg twice daily)
Study: 3683021
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg
Study: 2655691
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Ibuprofen and Indomethacin)
Study: 31195902
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment only (Control)
Study: 26048780
Drug: H4:IC31 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: H4:IC31 (5, 15, 50, or 150 μg with 500nmol IC31)
Study: 16449816
Drug: Cetirizine and
Normalized name: Cetirizine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine and theophylline (200 mg twice daily)
Study: 9265948
Drug: Mirtazapine (5-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (5-35 mg/day)
Study: 9265948
Drug: Amitriptyline (40-280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (40-280 mg/day)
Study: 22519919
Drug: Imeglimin 1000
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 1000 mg twice daily
Study: 30636830
Drug: Oxaceprol 200
Normalized name: oxaceprol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaceprol 200 mg thrice daily
Study: 30636830
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg thrice daily
Study: 26437063
Drug: Cyclosporine (CSA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CSA) with target blood concentration of 500 ng/ml
Study: 26437063
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) with target blood concentration of 15 ng/ml
Study: 14563464
Drug: Thiocolchicoside (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiocolchicoside (4 mg-2 ml) administered twice daily for 5 days
Study: 7633976
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant as a topical haemostatic agent
Study: 6401753
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, by mouth)
Study: 29092885
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (42 mg elemental Fe/d)
Study: 30413211
Drug: Biological implants
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological implants (Permacol™, Medtronic)
Study: 27054679
Drug: Three combat
Normalized name: Provita Combat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three combat rations plus four 250-kcal protein-based bars (PRO, 20 g protein)
Study: 27054679
Drug: Three combat
Normalized name: Provita Combat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three combat rations plus four 250-kcal carbohydrate-based bars (CHO, 48 g carbohydrate)
Study: 19889062
Drug: Fesoterodine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 12 mg
Study: 18044291
Drug: ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.4 mg/kg
Study: 18044291
Drug: thiopental 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiopental 0.5 mg/kg
Study: 18044291
Drug: meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 0.5 mg/kg
Study: 18044291
Drug: lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1 mg/kg
Study: 20394247
Drug: saline 3
Normalized name: CVS Saline 3.0% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 3 ml
Study: 12105362
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg/d
Study: 10394155
Drug: Endovascular graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular graft (EVG) treatment (22 patients, 14 bifurcated, 8 tube)
Study: 7590615
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load (0.75 g/kg BW per os, OGTT)
Study: 7590615
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose bolus (25 g i.v., IVGTT)
Study: 29510649
Drug: Letrozole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5 mg)
Study: 30184105
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (100 mg)
Study: 29955768
Drug: pegcantratinib, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegcantratinib, 0.5% (wt/wt), applied once daily for 12 weeks
Study: 29955768
Drug: placebo, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, applied once daily for 12 weeks
Study: 29955768
Drug: pegcantratinib, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegcantratinib, 0.5% (wt/wt), applied once daily for 4 weeks (phase 1b)
Study: 19155372
Drug: Semisynthetic penicillins
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semisynthetic penicillins (SSPs) including amoxicillin, ampicillin, pivampicillin
Study: 17448413
Drug: Spironolactone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (20 mg daily)
Study: 11555062
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg once daily for 6 weeks
Study: 28160494
Drug: Midazolam 5
Normalized name: midazolam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 5 mg - Droperidol 5 mg
Study: 465271
Drug: Droperidol 10
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 10 mg
Study: 23303067
Drug: Craving in
Normalized name: BENZALKONIUM CHLORIDE 13 mg in 1 mL TOPICAL SPRAY [Skin Crave non-alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craving in the week before treatment
Study: 21499196
Drug: Glutamine-enriched total
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched total parenteral nutrition (GE-TPN) solution consisting of 0.4 g/kg/day of l-alanine-glutamine dipeptide
Study: 21499196
Drug: Standard total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard total parenteral nutrition (S-TPN)
Study: 21499196
Drug: Glutamine-enriched total
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched total parenteral nutrition (GE-TPN) solution
Study: 18000176
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day pioglitazone for 16 weeks
Study: 9989513
Drug: Pion radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pion radiation therapy
Study: 9989513
Drug: Conventional external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional external beam photon therapy
Study: 7590426
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (350 ml)
Study: 7590426
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie orange cordial (50 ml)
Study: 449951
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B and flucytosine combination therapy
Study: 31661438
Drug: Composite mesh
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite mesh (Ventralex Patch)
Study: 28260702
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg) twice daily
Study: 28260702
Drug: Sitagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg) once daily
Study: 15193811
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroxine (T4) therapy
Study: 11208941
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of oral Lipiodol
Study: 2736096
Drug: topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical fluorouracil
Study: 31116102
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy with diaphragmatic breathing and biofeedback therapy
Study: 31116102
Drug: Baclofen at
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen at a dose of 10 mg three times daily
Study: 28179221
Drug: Daily sugar-sweetened
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sugar-sweetened beverage consumption